FGF2 and fibrosarcoma: Again, neither VEGF blockade nor imatinib monotherapy produced any significant antitumor activity in FGF-2+ fibrosarcomas (Fig. 4b, c), indicating that FGF-2 significantly contributes to development of drug resistance through a compensatory mechanism.